News

• Autorità nazionali / Area Liver 23 febbraio 2024

  SCREENING HCV ulteriormente prorogato fino al 31 dicembre 2024 con DECRETO 29 dicembre 2023 (GU Serie Generale n. 44 del 22-2-2024)

• Prodotti competitors 23 febbraio 2024

  tislelizumab (Tizveni): CHMP positive opinion for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

• Prodotti competitors / Area Onco-Ema, Area Kite 23 febbraio 2024

  Carvykti (ciltacabtagene autoleucel): positive CHMP opinion for extension indication in 2L treatment of adult patients with relapsed and refractory multiple myeloma

• Prodotti competitors / Area Oncology 23 febbraio 2024

  pembrolizumab (Keytruda): positive CHMP opinion to extension indication to include the pre- and post-operative treatment of adults whose non-small cell lung carcinoma can be removed by surgery and who are at high risk of recurrence.

• Prodotti competitors / Area Oncology 23 febbraio 2024

  Roche initiates a new Phase 3 clinical trial with tiragolumab (anti-TIGIT) in the resectable lung cancer (NSCLC) setting

• Autorità nazionali / Area Liver 20 febbraio 2024

  Epatite C: aggiornamento del 19 febbraio 2024 sui pazienti arruolati

• Prodotti competitors / Area Oncology 19 febbraio 2024

  Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

• Prodotti competitors / Area Kite, Area Onco-Ema 16 febbraio 2024

  FDA Oncologic Drugs Advisory Committee (ODAC) will review Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene) applications to broaden the labels for use in multiple myeloma early lines of treatment

• Prodotti competitors / Area Oncology 16 febbraio 2024

  Capivasertib (Truqap): delays in Phase 1b/3 CAPItello-290 trial evaluating capivasertib + CDK4/6i + fulvestrant in HR+/HER2- metastatic breast cancer

• Normativa europea Regulatory news 15 febbraio 2024

  Launch of new HMA-EMA catalogues of real-world data sources and studies